Trial Profile
A 16 Week Multi-Center, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Very Elderly Patients With Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2011
Price :
$35
*
At a glance
- Drugs Valsartan/hydrochlorothiazide (Primary) ; Hydrochlorothiazide; Valsartan
- Indications Essential hypertension; Hypertension
- Focus Therapeutic Use
- Acronyms VALVET
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension
- 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
- 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.